Clinical trial NCT03782207: A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Official title: A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Urothelial Carcinoma
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Hepatocellular Carcinoma
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2018-12-20
Enrollment: 2756
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants diagnosed with locally advanced /mUC previously treated with platinum-containing chemotherapy, participants diagnosed with locally advanced/metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy, participants diagnosed with extensive-stage small cell lung cancer (ES-SCLC), participants diagnosed with metastatic NSCLC previously untreated,and participants diagnosed with locally unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.

Brief summary: This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.

Detailed description: The study will be split into separate cohorts based on the approved indications for atezolizumab treatment, excluding cisplatin ineligible participants receiving atezolizumab as first line of therapy (LOT1) for locally advanced/metastatic urothelial cancer (locally advanced/metastatic UC). The study may be amended for inclusion of new cohorts as these are approved in the participating countries. Participants will be included into each cohort based on their indication for receiving atezolizumab.

Eligibility criteria: Inclusion Criteria:

* Patient must have one of the following confirmed diagnoses for which atezolizumab is locally approved in the SmPC: (1) As monotherapy for the treatment of adult patients with locally advanced/metastatic UC after prior platinum-containing chemotherapy (Cohort 1 LOT2+mUC) or (2) As monotherapy for the treatment of adult patients with locally advanced/metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab (Cohort 2 LOT2+NSCLC) or (3) In combination with bevacizumab, paclitaxel and carboplatin for the first line treatment of adult patients with metastatic non-squamous NSCLC. Patients with EGFR activating mutations or ALK- positive tumour mutations should also have received targeted therapy (Cohort 3 LOT1 NSCLC) or (4) In combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (Cohort 4 LOT1 ES-SCLC) or (5) As a monotherapy, for the treatment of metastatic NSCLC with high PD-L1 expression, previously untreated (Cohort 5 LOT1 NSCLC) or (6) In combination with bevacizumab for unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy (Cohort 6 LOT1 HCC) .
* Patient is administered atezolizumab therapy for the first time.
* Decision to administer atezolizumab must be made and documented prior to inclusion into the study and must follow local clinical practice.

Exclusion Criteria:

* Patients not receiving treatment for a disease with atezolizumab according to standard of care and in line with the current summary of product characteristics (SPC) or local labelling. Cisplatin ineligible patients receiving atezolizumab LOT1 for the treatment of locally advanced/metastatic UC patients will be excluded
* Concomitant anti-cancer therapy at the time of starting atezolizumab on the index date not part of locally approved combination therapy with atezolizumab.
* Treatment with atezolizumab as part of a clinical trial or for compassionate use as part of a pre-approval or compassionate use program.
* Patients not receiving atezolizumab, but a biosimilar or non-original biologic.

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: Index date up to approximately 6 years
measure: OS at 2 Years
timeFrame: After index date up to 2 years
Secondary outcomes:
measure: Time to Loss of Clinical Benefit (TTLCB)
timeFrame: Index date up to approximately 6 years
measure: Progression Free Survival (PFS)
timeFrame: Index date up to approximately 6 years
measure: Objective Response Rate (ORR)
timeFrame: After index date up to approximately 6 years
measure: Time to Response
timeFrame: Index date up to approximately 6 years
measure: Duration of Response (DoR)
timeFrame: Index date up to approximately 6 years
measure: Disease Control Rate (DCR)
timeFrame: From 12 weeks after index date up to approximately 6 years
measure: Duration of DCR
timeFrame: After index date up to approximately 6 years
measure: EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Score
timeFrame: Index date or after ICF signature, & approx. at 6, 12, and 24 weeks of treatment; then at approx. 3 months, 6 months, 12 months, & every 12 months thereafter until end of study (study planned duration up to approximately 6 years)
measure: Number of Paricipants with Disease Stage TNM and IUCC
timeFrame: At index date (Index date is the date of administration of the first ever dose of atezolizumab for each patient.)
measure: Number of Participants at Each Level of Karnofsky or ECOG Performance Status
timeFrame: At index date (Index date is the date of administration of the first ever dose of atezolizumab for each patient.
measure: Total Number of Infusions of Atezolizuamb
timeFrame: Treatment period until discontinuation (up to approximately 6 years)
measure: Duration of Treatment With Atezolizumab
timeFrame: Index date until date of treatment discontinuation (up to approximately 6 years)
measure: Time to initiation of the first subsequent cancer-related therapy
timeFrame: Up to approximately 6 years
measure: Percentage of Participants with Adverse Events
timeFrame: Up to approximately 6 years
measure: Number of Lines of Prior and Subsequent Cancer-Related Therapies
timeFrame: Up to approximately 6 years
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: Hospital Universitario Austral
city: Caba
country: Argentina
facility: Consultorio Privado Korbenfeld
city: Ciudad Autonoma Buenos Aires
country: Argentina
facility: Hospital Italiano de Buenos Aires
city: Ciudad Autónoma de Buenos Aires
country: Argentina
facility: Lucen S.A.
city: Cordoba
country: Argentina
facility: Sanatorio Allende
city: Rosario
country: Argentina
facility: Sanatorio de la Mujer
city: Santa Rosa
country: Argentina
facility: Fundacion Koriza
city: Klagenfurt
country: Austria
facility: Klinikum Klagenfurt
city: Krems
country: Austria
facility: Landesklinikum Krems
city: Vöcklabruck
country: Austria
facility: Salzkammergut-Klinikum Voecklabruck
city: Wels
country: Austria
facility: Klinikum Wels-Grieskirchen
city: Brasschaat
country: Belgium
facility: AZ KLINA
city: Mechelen
country: Belgium
facility: AZ St Maarten Campus Leopoldstr
city: Mont-godinne
country: Belgium
facility: CHU UCL Mont-Godinne
city: Oostende
country: Belgium
facility: AZ Damiaan
city: Roeselare
country: Belgium
facility: AZ Delta (Campus Rumbeke)
city: Sint-Truiden
country: Belgium
facility: Sint Trudo Ziekenhuis
city: Sao Paulo
country: Brazil
facility: Beneficencia Portuguesa de Sao Paulo
state: São Paulo
city: Burgas
country: Bulgaria
facility: Complex Oncology Center Burgas
city: Panagyurishte
country: Bulgaria
facility: Multiprofile Hospital for Active Treatment Uni Hospital
city: Pleven
country: Bulgaria
facility: Umhat Dr Georgi Stranski
city: Plovdiv
country: Bulgaria
facility: University Hospital Palmed
city: Plovdiv
country: Bulgaria
facility: Complex Oncological Center - Plovdiv, EOOD
city: Plovdiv
country: Bulgaria
facility: Complex Oncology Center - Plovdiv First Internal Chemotherapy Department
city: Plovdiv
country: Bulgaria
facility: DDODIU-Plovdiv, EOOD
city: Ruse
country: Bulgaria
facility: Complex Oncological Center-Ruse EOOD
city: Sofia
country: Bulgaria
facility: Tokuda Hospital
city: Sofia
country: Bulgaria
facility: UMHAT "Sv. Ivan Rilski", EAD
city: Sofia
country: Bulgaria
facility: MBAL Serdika EOOD
city: Sofia
country: Bulgaria
facility: MHAT SofiaMed
city: Varna
country: Bulgaria
facility: Specialized Hospital for Active Cancer Treatment, Dr. Mark Antonov Markov - Varna Ltd
city: Santiago
country: Chile
facility: Centro de Estudios Clínicos SAGA
city: Cali
country: Colombia
facility: Angiografia del Occidente
city: Cali
country: Colombia
facility: Fundacion Clinica Valle del Lili
city: Medellin
country: Colombia
facility: Hospital Pablo Tobon Uribe
city: Medellin
country: Colombia
facility: Clinica ASTORGA
city: Osijek
country: Croatia
facility: Clinical Hospital Centre Osijek
city: Split
country: Croatia
facility: Klinicki Bolnicki Centar Split
city: Zagreb
country: Croatia
facility: Clinical Hospital Center Sestre Milosrdnice
city: Zagreb
country: Croatia
facility: Clinical Hospital Centre Zagreb
city: Alexandria
country: Egypt
facility: SUN Oncology center- Alexandria
city: Cairo
country: Egypt
facility: Yasser Abdel Kader Private Clinic
city: Cairo
country: Egypt
facility: Air Force Specialized Hospital
city: Cairo
country: Egypt
facility: Barsoum Oncology Center
city: Cairo
country: Egypt
facility: Cairo Oncology Center
city: Cairo
country: Egypt
facility: International Medical Center
city: Tallinn
country: Estonia
facility: North Estonia Medical Centre Foundation
city: Tartu
country: Estonia
facility: Tartu Uni Hospital
city: Agen
country: France
facility: Clinique Du Docteur Calabet
city: Aix En Provence
country: France
facility: Ch Du Pays D Aix
city: Amiens
country: France
facility: Clinique de l'Europe
city: Angers
country: France
facility: Centre Hospitalier Uni Ire
city: Antony
country: France
facility: Hopital Prive D Antony
city: Avignon
country: France
facility: CHG Henri Dufaut médecine interne-onco-hematologie
city: Beauvais
country: France
facility: CH de Beauvais
city: Besancon
country: France
facility: Hopital Jean Minjoz
city: Beziers
country: France
facility: Ch De Beziers
city: Bordeaux
country: France
facility: Clinique Tivoli
city: Bordeaux
country: France
facility: Polyclinique Bordeaux Nord Aquitaine
city: Caen
country: France
facility: Hopital Cote De Nacre
city: Chambery
country: France
facility: Ch De Chambery
city: Chambray Les Tours
country: France
facility: Oncologie 37
city: Clermont-ferrand
country: France
facility: Hopital Gabriel Montpied
city: Compiegne
country: France
facility: Ch De Compiegne
city: Creil
country: France
facility: Ch Laennec
city: Dijon
country: France
facility: Centre Georges Francois Leclerc
city: Eaubonne
country: France
facility: Hopital Simone Veil Eaubonne
city: GAP
country: France
facility: Chi Alpes Du Sud Site De Gap
city: Gleize
country: France
facility: Hopital Nord Ouest
city: La Rochelle
country: France
facility: Ch Saint Louis
city: La Source
country: France
facility: Hopital La Source
city: Le Coudray
country: France
facility: Hopital Louis Pasteur
city: Le Mans
country: France
facility: Centre Hospitalier Du Mans
city: Lille
country: France
facility: Hôpital Privé La Louviere
city: Limoges
country: France
facility: Hopital Dupuytren
city: Lorient
country: France
facility: Ch Bretagne Sud Site Scorff
city: Lyon
country: France
facility: Hopital Privé Jean Mermoz
city: Marseille
country: France
facility: Hopital Europeen
city: Montpellier
country: France
facility: Clinique Clementville
city: Montpellier
country: France
facility: Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque
city: Mulhouse
country: France
facility: Hopital Emile Muller
city: Nimes
country: France
facility: Hopital Caremeau
city: Nimes
country: France
facility: Polyclinique Kenval
city: Paris
country: France
facility: Institut Curie
city: Paris
country: France
facility: Hopital Cochin
city: Paris
country: France
facility: Hopital Europeen Georges Pompidou
city: PAU
country: France
facility: Centre Hospitalier
city: Perpignan
country: France
facility: Centre Catalan D' Oncologie
city: Pringy
country: France
facility: Ch Annecy - Genevois
city: Reims
country: France
facility: Hopital De La Maison Blanche
city: Saint Nazaire
country: France
facility: Clinique Mutualiste L Estuaire
city: Saint Priest En Jarez
country: France
facility: Hopital Nord
city: Sarreguemines
country: France
facility: Hopital Robert Pax
city: St Quentin
country: France
facility: Ch De Saint Quentin
city: Toulon
country: France
facility: Hopital Sainte Musse
city: Toulouse
country: France
facility: Hopital Larrey
city: Valence
country: France
facility: Centre Hospitalier de Valence
city: Valenciennes Cedex
country: France
facility: Service de pneumologie Clinique médico-chirurgicale Tessier
city: Vannes
country: France
facility: Ch Bretagne Atlantique
city: Vantoux
country: France
facility: Hopital Robert Schuman
city: Budapest
country: Hungary
facility: Orszagos Koranyi TBC es Pulmonologiai Intezet
city: Budapest
country: Hungary
facility: Semmelweis Egyetem, AOK, Pulmonologiai Klinika
city: Debrecen
country: Hungary
facility: Debreceni Egyetem, Klinikai Kozpont, Tudogyogyaszati Klinika
city: Pecs
country: Hungary
facility: University of Pecs
city: Törökbálint
country: Hungary
facility: Református Pulmonológiai Centrum
city: Ahmedabad
country: India
facility: HCG Cancer Center
state: Gujarat
city: Surat CITY
country: India
facility: Sunshine Global Hospital (A unit of Baroda Medicare Pvt Ltd)
state: Gujarat
city: Bangalore
country: India
facility: Manipal Hospital
state: Karnataka
city: Kochi
country: India
facility: Aster Medcity
state: Kerala
city: Kozhikode
country: India
facility: MVR Cancer Centre and Research Institute
state: Kerala
city: Mumbai
country: India
facility: MOC Cancer Care & Research Centre
state: Maharashtra
city: Gachibowli
country: India
facility: AIG Hospitals
state: Telangana
city: L?Aquila
country: Italy
facility: Ospedale San Salvatore, UOC Oncologia
state: Abruzzo
city: Reggio Calabria
country: Italy
facility: Grande Ospedale Metropolitano
state: Calabria
city: Napoli
country: Italy
facility: Az. Osp. Monaldi
state: Campania
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori Fondazione G. Pascale
state: Campania
city: Modena
country: Italy
facility: A.O. Universitaria Policlinico Di Modena
state: Emilia-Romagna
city: Roma
country: Italy
facility: Azienda Ospedaliera San Camillo Forlanini
state: Lazio
city: Sora
country: Italy
facility: Ospedale S.S. Trinità Nuovo
state: Lazio
city: Genova
country: Italy
facility: IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST)
state: Liguria
city: Milano
country: Italy
facility: Ospedale Maggiore Policlinico
state: Lombardia
city: Milano
country: Italy
facility: Asst Santi Paolo E Carlo
state: Lombardia
city: Milano
country: Italy
facility: Asst Grande Ospedale Metropolitano Niguarda
state: Lombardia
city: Varese
country: Italy
facility: Ospedale Di Circolo E Fondazione Macchi
state: Lombardia
city: Macerata
country: Italy
facility: Ospedale Di Macerata
state: Marche
city: Alessandria
country: Italy
facility: Ospedale Civile SS. Antonio E Biagio DI Alessandria
state: Piemonte
city: Cagliari
country: Italy
facility: Ospedale Oncologico A.Businco
state: Sardegna
city: Sassari
country: Italy
facility: Azienda Ospedaliero Universitaria Di Sassari
state: Sardegna
city: Catania
country: Italy
facility: Az Ospedaliera Nuovo Garibaldi Quartiere Nesima
state: Sicilia
city: Messina
country: Italy
facility: Az. Osp. Uni. Ria Policlinico G. Martino
state: Sicilia
city: Firenze
country: Italy
facility: Azienda Ospedaliero Universitaria Careggi
state: Toscana
city: Firenze
country: Italy
facility: Azienda Ospedaliero-Universitaria Careggi
state: Toscana
city: Lido Di Camaiore
country: Italy
facility: Ospedale Nuovo Della Versilia
state: Toscana
city: Verona
country: Italy
facility: A.O.U. Integrata Verona - Policlinico G.B. Rossi
state: Veneto
city: Vicenza
country: Italy
facility: Azienda ULSS 8 Berica
state: Veneto
city: Kuwait
country: Kuwait
facility: Kuwait Cancer control center
city: Shuwakh Industrial
country: Kuwait
facility: Kuwait Cancer control center
city: Beirut
country: Lebanon
facility: Saint George Hospital
city: Bsalim, Mount Lebanon-Metn
country: Lebanon
facility: Middle East Institute of Health Hospital
city: Kaunas
country: Lithuania
facility: Hospital of Lithuanian University of Health Sciences Kaunas Clinics Public Institution
city: Vilnius
country: Lithuania
facility: National Cancer Institute
city: Mexico City
country: Mexico
facility: Medica sur Hospital
state: Mexico CITY (federal District)
city: Monterrey
country: Mexico
facility: Clinica Opcion Oncologia S.A. de C.V.
state: Nuevo LEON
city: San Pedro Garza García
country: Mexico
facility: Oncare
state: Nuevo LEON
city: Amsterdam
country: Netherlands
facility: Onze Lieve Vrouwe Gasthuis, locatie Oost
city: Eindhoven
country: Netherlands
facility: Catharina ziekenhuis
city: Leeuwarden
country: Netherlands
facility: Medisch Centrum Leeuwarden
city: Zaandam
country: Netherlands
facility: Zaans Medisch Centrum
city: Muscat
country: Oman
facility: Royal Hospital
city: Muscat
country: Oman
facility: Sultan Qaboos Comprehensive Cancer Care & Research Center
city: Lahore
country: Pakistan
facility: Shaukat Khanum Memorial Cancer Hospital
state: Punjab (province)
city: Karachi
country: Pakistan
facility: Aga Khan University
state: Sindh (province)
city: ?ód?
country: Poland
facility: WZZOZ Centrum Leczenia Chorob Pluc i Rehabilitacji
city: ?ód?
country: Poland
facility: Wojewódzki Szpital Specjalistyczny im. M. Kopernika w ?odzi
city: Bielsko-Bia?a
country: Poland
facility: Beskidzkie Centrum Onkologii - Szpital Miejski im. Jana Pawla II
city: Bydgoszcz
country: Poland
facility: Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
city: Bystra
country: Poland
facility: Centrum Pulmonologii i Torakochirurgii
city: Elblag
country: Poland
facility: Wojewodzki Szpital Zespolony
city: Grudzi?dz
country: Poland
facility: Regionalny Szpital Specjalistyczny im. W. Bieganskiego
city: Lublin
country: Poland
facility: Uniwersytecki Szpital Kliniczny nr 4 w Lublinie
city: Olsztyn
country: Poland
facility: Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
city: Otwock
country: Poland
facility: Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
city: Pozna?
country: Poland
facility: Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu
city: Warszawa
country: Poland
facility: Instytut Gruzlicy i Chorob P?uc
city: Warszawa
country: Poland
facility: Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
city: Wroc?aw
country: Poland
facility: Dolno?L?Skie Centrum Onkologii, Pulmonologii I Hematologii
city: Coimbra
country: Portugal
facility: Hospital Geral
city: Lisboa
country: Portugal
facility: Centro Clinico Champalimaud
city: Lisboa
country: Portugal
facility: Hospital Pulido Valente
city: Matosinhos
country: Portugal
facility: Hospital Pedro Hispano
city: Porto
country: Portugal
facility: Centro Hospitalar do Porto ? Hospital de Santo António
city: Porto
country: Portugal
facility: Hospital CUF Porto
city: Vila Nova De Gaia
country: Portugal
facility: CHVNG/E_Unidade 1
city: Bucharest
country: Romania
facility: Institutul Clinic Fundeni Bucuresti
city: Cluj-Napoca
country: Romania
facility: Institutul Regional de Gastroenterologie si Hepatologie Prof. Dr. Octavian Fodor
city: Barnaul
country: Russian Federation
facility: Altai Regional Oncological Center
state: Altaj
city: Arkhangelsk
country: Russian Federation
facility: Arkhangelsk Regional Clinical Oncology Dispensary
state: Arhangelsk
city: UFA
country: Russian Federation
facility: Bashkirian Republican Clinical Oncology Dispensary
state: Baskortostan
city: Krasnoyarsk
country: Russian Federation
facility: Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky
state: Krasnodar
city: Moscow
country: Russian Federation
facility: FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF
state: Moskovskaja Oblast
city: Saint-Petersburg
country: Russian Federation
facility: S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
state: Sankt Petersburg
city: Sankt-peterburg
country: Russian Federation
facility: Medical Clinic "AB Medical group"
state: Sankt Petersburg
city: Sankt-peterburg
country: Russian Federation
facility: EuroCityClinic
state: Sankt Petersburg
city: Kazan
country: Russian Federation
facility: Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic
state: Tatarstan
city: Kaluga
country: Russian Federation
facility: SBIH Kaluga Region Clinical Oncology Dispensary
city: Tver
country: Russian Federation
facility: Tver Regional Oncology Clinical Dispensary
city: Singapore
country: Singapore
facility: Tan Tock Seng Hospital
city: Ljubljana
country: Slovenia
facility: Institute of Oncology Ljubljana
city: Ljubljana
country: Slovenia
facility: University Medical Center Ljubljana
city: Maribor
country: Slovenia
facility: Univerzitetni klini?ni center Maribor
city: Almería
country: Spain
facility: Complejo Hospitalario Torrecardenas
state: Almeria
city: Mataro
country: Spain
facility: Hospital General de Mataro
state: Barcelona
city: Sabadell
country: Spain
facility: Corporacio Sanitaria Parc Tauli
state: Barcelona
city: Palma De Mallorca
country: Spain
facility: Hospital Universitario Son Espases
state: Islas Baleares
city: Santiago de Compostela
country: Spain
facility: Complejo Hospitalario Universitario de Santiago (CHUS)
state: LA Coruna
city: San Sebastian de Los Reyes
country: Spain
facility: Hospital Infanta Sofia
state: Madrid
city: Pamplona
country: Spain
facility: Clinica Universitaria de Navarra
state: Navarra
city: Pamplona
country: Spain
facility: Complejo Hospitalario de Navarra
state: Navarra
city: La Laguna
country: Spain
facility: Hospital Universitario de Canarias
state: Tenerife
city: Santa Cruz de Tenerife
country: Spain
facility: Complejo Hospitalario Nuestra Señora de la Candelaria
state: Tenerife
city: Badajoz
country: Spain
facility: Hospital Universitario Infanta Cristina
city: Barcelona
country: Spain
facility: Hospital Universitari Dexeus - Grupo Quironsalud
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
city: Burgos
country: Spain
facility: Complejo Asistencial Universitario De Burgos
city: Caceres
country: Spain
facility: Hospital San Pedro De Alcantara
city: Granada
country: Spain
facility: Hospital Clinico de Granada
city: Jaen
country: Spain
facility: Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
city: Leon
country: Spain
facility: Complejo Asistencial Universitario de Leon
city: Lugo
country: Spain
facility: Hospital Lucus Augusti
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Madrid
country: Spain
facility: Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal
city: Madrid
country: Spain
facility: Hospital Universitario Puerta de Hierro
city: Madrid
country: Spain
facility: Hospital Quiron de Madrid
city: Orense
country: Spain
facility: Complejo Hospitalario de Orense
city: Segovia
country: Spain
facility: Hospital General de Segovia
city: Sevilla
country: Spain
facility: Hospital Univ. Nuestra Señora de Valme
city: Valladolid
country: Spain
facility: Hospital Clinico Universitario de Valladolid
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet
city: Al Ain
country: United Arab Emirates
facility: Tawam Hospital
city: Barnet
country: United Kingdom
facility: Barnet Hospital
city: Bath
country: United Kingdom
facility: Royal United Hospital
city: Bebington
country: United Kingdom
facility: Clatterbridge Cancer Centre
city: Birmingham
country: United Kingdom
facility: Queen Elizabeth Hospital
city: Birmingham
country: United Kingdom
facility: Heartlands Hospital
city: Burnley
country: United Kingdom
facility: East Lancashire Hospitals NHS Trust
city: Cambridge
country: United Kingdom
facility: Addenbrookes Hospital
city: Cardiff
country: United Kingdom
facility: Velindre Cancer Centre
city: Cottingham
country: United Kingdom
facility: Castle Hill Hospital
city: Guildford
country: United Kingdom
facility: Royal Surrey County Hospital
city: Harrow
country: United Kingdom
facility: Northwick Park Hospital
city: Huddersfield
country: United Kingdom
facility: Huddersfield Royal Infirmary
city: Keighley
country: United Kingdom
facility: Airedale General Hospital
city: Kingston upon Thames
country: United Kingdom
facility: Royal Marsden Hospital
city: Leeds
country: United Kingdom
facility: St James Hospital
city: London
country: United Kingdom
facility: St Bartholomew's Hospital
city: London
country: United Kingdom
facility: Royal Free Hospital
city: London
country: United Kingdom
facility: Guys and St Thomas Hospital
city: London
country: United Kingdom
facility: Queen Elizabeth Hospital
city: London
country: United Kingdom
facility: St George's Hospital
city: London
country: United Kingdom
facility: Royal Marsden Hospital - Fulham
city: London
country: United Kingdom
facility: Hammersmith Hospital
city: London
country: United Kingdom
facility: Charing Cross Hospital
city: Maidstone
country: United Kingdom
facility: Maidstone Hospital
city: Manchester
country: United Kingdom
facility: The Christie
city: Middlesbrough
country: United Kingdom
facility: James Cook Hospital
city: Newcastle upon Tyne
country: United Kingdom
facility: Freeman Hospital
city: Nottingham
country: United Kingdom
facility: Nottingham City Hospital
city: Oxford
country: United Kingdom
facility: Churchill Hospital
city: Preston
country: United Kingdom
facility: Royal Preston Hospital
city: Sheffield
country: United Kingdom
facility: Weston Park Hospital
city: Stoke on Trent
country: United Kingdom
facility: Royal Stoke University Hospital
city: Sutton
country: United Kingdom
facility: Royal Marsden Hospital (Sutton)
city: Torquay
country: United Kingdom
facility: Torbay Hospital
city: Truro
country: United Kingdom
facility: Royal Cornwall Hospital
city: Wakefield
country: United Kingdom
facility: Pinderfields General Hospital
city: Wiltshire
country: United Kingdom
facility: Great Western Hospitals NHS Foundation Trust.
city: Wolverhampton
country: United Kingdom
facility: New Cross Hospital
city: York
country: United Kingdom
facility: The York Hospital
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: